Strengths

Specialty plasma-derived product focus can support niche demand visibility versus broader hospital suppliers, but peers with larger portfolios still enjoy stronger scale and diversification.

Current ratio of 2.72 and quick ratio of 2.09 indicate adequate near-term liquidity, which is better than many leveraged small-cap medtech peers facing tighter working-capital buffers.

Debt-to-equity of 0.18 suggests balance-sheet leverage is contained relative to more indebted peers, limiting refinancing pressure and preserving flexibility for operations.

Despite negative TTM ROIC of -7.7%, the company’s niche positioning can still protect some customer relationships better than commoditized competitors in adjacent infusion markets.

Weaknesses

TTM ROIC of -7.7% shows capital is not earning its cost, leaving KRMD structurally behind profitable peers that convert invested capital into durable returns.

Cash conversion cycle of 83.3 days is long for a small medical-products business, tying up working capital more than faster-turn peers and constraining reinvestment.

Net debt to EBITDA of 5.0 signals elevated leverage versus stronger peers, increasing financial fragility and reducing strategic optionality if operating performance remains weak.

Limited scale versus larger specialty-device peers likely keeps procurement, manufacturing, and distribution costs less efficient, which pressures margins and weakens competitive positioning.

Opportunities

If management shortens the 83-day cash conversion cycle, working-capital release could improve liquidity and fund growth more efficiently than peers with similarly slow turns.

A stronger balance sheet than more levered peers may allow selective commercial investment, potentially improving share in niche infusion and plasma-adjacent channels.

Specialty product concentration can support deeper customer penetration if reimbursement and clinical adoption remain stable, creating room for incremental share gains versus broader competitors.

Operational improvement in returns on capital could narrow the gap with peers, but the current negative ROIC means the upside depends on execution rather than structural advantage.

Threats

Persistent negative ROIC raises the risk that peers with better economics outcompete KRMD on pricing, service, and reinvestment capacity over the next several years.

High leverage relative to earnings leaves the company more exposed than stronger peers to covenant pressure, refinancing costs, and earnings volatility.

Long cash conversion cycle increases vulnerability to inventory or receivables shocks, especially versus peers with faster turnover and stronger operating discipline.

Larger diversified competitors can absorb product, regulatory, or channel disruptions more easily, making KRMD’s narrower niche position structurally more fragile.

Overall Score

KRMD’s niche positioning and acceptable liquidity are outweighed by negative returns on capital, elevated leverage, and slower working-capital efficiency versus peers.